Akero Therapeutics Inc
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
A box of Ozempic sits on a table in North Tyneside, Britain, Oct. 31, 2023. Lee Smith | Reuters Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market. Net profit for the […]
Read More
Stocks making the biggest moves midday: Oracle, Ferrari, Delta, Albemarle and more
Check out the companies making the biggest moves in midday trading: Oracle — Shares of the software company rose more than 3% on Thursday after Baird initiated coverage with a outperform rating and a $365 price taget. The firm said Oracle has a strong position in the artificial intelligence growth story. The stock has had […]
Read More
Novo Nordisk shares slip after pharma giant announces $4.7 billion U.S. acquisition
LONDON — Shares of Danish pharmaceutical giant Novo Nordisk fell 1.1% on Thursday after the company announced plans to acquire U.S. biotech firm Akero Therapeutics. The deal will see Novo pay $54 per share, valuing Akero at $4.7 billion, with the acquisition also including a contingent value right of $6 per share, potentially adding another […]
Read More
Stocks making the biggest moves premarket: Ferrari, PepsiCo, Delta, Akero Therapeutics and more
Check out the companies making the biggest moves in premarket trading: Ferrari — The luxury carmaker tumbled nearly 14% after it trimmed its electrification targets . Ferrari said it expects its 2030 sports car model line-up to be made up of 40% internal combustion engine cars, 40% hybrid and 20% fully electric vehicles. That’s down […]
Read More
Novo Nordisk to buy Akero for up to $5.2 billion for promising liver drug
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters Novo Nordisk said on Thursday it would buy Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal […]
Read More
Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming
3D Illustration of a human liver organ. magicmine | iStock | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for […]
Read More
Here are JPMorgan’s favorite stock picks for August
JPMorgan added three new names to its top stocks list for August, including a biotechnology company and a stainless steel manufacturer. The investment firm named Akero, Carpenter Technology and Alabama-based Regions Financial to its focus list, according to a Monday note. Analysts submit their best ideas for near term-, growth-, value- and short investment strategies. […]
Read More